Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents. The biotechnology company posted revenue of $73.5 million in the period, beating Street forecasts. Three ...

Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

An update from Aurinia Pharmaceuticals ( (AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third quarter of 2025, with LUPKYNIS sales increasing by 27% ...

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

Dr. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...